Detalles de la búsqueda
1.
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Blood
; 134(21): 1811-1820, 2019 11 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31558467
2.
A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.
Br J Haematol
; 177(2): 243-253, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28220479
3.
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.
Br J Haematol
; 176(3): 412-420, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27982425
4.
Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.
Haematologica
; 101(7): e295-8, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27151992
5.
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Lancet Haematol
; 8(4): e254-e266, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33631112
6.
The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence.
BMC Cancer
; 10: 108, 2010 Mar 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-20307320
7.
TLE3 as a candidate biomarker of response to taxane therapy.
Breast Cancer Res
; 11(2): R17, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19309506
8.
A novel five-antibody immunohistochemical test for subclassification of lung carcinoma.
Mod Pathol
; 22(8): 1032-43, 2009 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-19430419
9.
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
Lancet Haematol
; 6(2): e100-e109, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30709431
10.
Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia.
Hemasphere
; 2(3): e39, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-31723767
11.
Community-based phase II trial of pentostatin, cyclophosphamide, and rituximab (PCR) biochemotherapy in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Cancer Biother Radiopharm
; 22(2): 185-93, 2007 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-17600465
12.
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma.
Blood Adv
; 1(2): 122-131, 2016 Dec 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-29296805
13.
Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma.
Leuk Lymphoma
; 55(10): 2335-40, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24471908
14.
Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
Lung Cancer
; 85(3): 420-8, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24997137
15.
Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study.
Cancer
; 113(9): 2512-7, 2008 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18816622
Resultados
1 -
15
de 15
1
Próxima >
>>